company background image
3371 logo

Corbus Pharmaceuticals Holdings DB:3371 Stock Report

Last Price

€12.00

Market Cap

€152.1m

7D

-13.7%

1Y

n/a

Updated

23 Dec, 2024

Data

Company Financials +

Corbus Pharmaceuticals Holdings, Inc.

DB:3371 Stock Report

Market Cap: €152.1m

My Notes

Capture your thoughts, links and company narrative

Corbus Pharmaceuticals Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Corbus Pharmaceuticals Holdings
Historical stock prices
Current Share PriceUS$12.00
52 Week HighUS$56.00
52 Week LowUS$12.00
Beta2.57
1 Month Change-22.58%
3 Month Change-34.43%
1 Year Changen/a
3 Year Change-30.87%
5 Year Change-91.56%
Change since IPO-84.91%

Recent News & Updates

Recent updates

Shareholder Returns

3371DE BiotechsDE Market
7D-13.7%-2.6%-2.0%
1Yn/a-13.2%6.8%

Return vs Industry: Insufficient data to determine how 3371 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 3371 performed against the German Market.

Price Volatility

Is 3371's price volatile compared to industry and market?
3371 volatility
3371 Average Weekly Movement10.2%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.4%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 3371's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 3371's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200919Yuval Cohenwww.corbuspharma.com

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.

Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary

How do Corbus Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
3371 fundamental statistics
Market cap€152.14m
Earnings (TTM)-€37.19m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3371 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$30.41m
Gross Profit-US$30.41m
Other ExpensesUS$8.29m
Earnings-US$38.70m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.18
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 3371 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 17:09
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Corbus Pharmaceuticals Holdings, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
George ZavoicoB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets